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comorbidities. Further understanding regarding the signal-
ing pathways of GDF-15 may help to discover next pieces 
in the exciting puzzle of GDF-15. Finally, as studies deal-
ing with normal level of GDF-15 in the healthy aged are 
lacking, it is possible that the higher values of GDF-15 val-
ues found in the present study represent values of GDF-15 
according to age more than CKD levels.
Keywords GDF-15 · Chronic kidney disease ·  
Iron · Inflammation · Hepcidin
Introduction
In the Baltimore Longitudinal study, 254 healthy partici-
pants (without CKD, hypertension, not treated with diuret-
ics) had periodical assessment of creatinine clearance in the 
period between 1958 and 1981 [1]. The mean decrease in 
creatinine clearance was 0.75 ml/min/year and was greater 
in patients who developed hypertension later during obser-
vation. In one in three patients, there was no fall in creati-
nine clearance. In NHANES III, an eGFR (MDRD) below 
60 ml/min was found in 11 % of subjects over 65 years 
without concomitant diabetes and hypertension, while this 
was found in only 0.1 and 1.2 % subjects aged 20–39 and 
40–59 years, respectively [2]. In our previous study, we 
found a very high prevalence of CKD up to 61 %, on the 
basis of estimated GFR/creatinine clearance, in elderly 
patients with coronary artery disease and normal serum 
creatinine level undergoing PCI [3].
One of the key pathomechanisms responsible for the 
progression of CKD is subclinical inflammation, which 
may be the result of decreasing clearance of uremic 
cytokines and oxidative stress. In some patients the cause 
of inflammation may be associated with concomitant 
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diseases, including heart failure, atherosclerosis, or pulmo-
nary disorders.
In most patients with CKD, there is a disruption in iron 
metabolism due to inflammation that may lead to anemia 
of inflammation (AI). However, iron deficiency (ID) is not 
necessarily linked to the occurrence of anemia. Elderly 
population is particularly vulnerable for the development of 
ID and AI.
The key element involved in iron metabolism is hepci-
din; however, studies on new indices of iron status are in 
progress. Hepcidin is an acute phase protein that is syn-
thesized to restrict the body’s iron stores and to prevent 
iron being requisitioned by invading microorganisms. One 
of the proteins involved in hepcidin-25 regulation and 
metabolism is growth differentiation factor-15 (GDF-15). 
GDF-15 is a member of transforming factor-β superfamily, 
which is secreted by erythroblasts as they mature. GDF-15 
concentrations are elevated in the situations associated with 
ineffective erythropoiesis, such as thalassemia syndromes 
or sickle cell syndromes as well as other conditions like 
inflammation, acute injury, or cancer [4]. Moreover, GDF-
15 is known as a cardiovascular risk marker independently 
of traditional risk factors such as CRP.
It has been shown that high concentration of GDF-15 
is responsible for the reduced synthesis of hepcidin [5]. 
Therefore, GDF-15 is potentially involved in iron homeo-
stasis. In patients with chronic kidney disease, serum con-
centration of GDF-15 is elevated [6]. GDF-15 is also pre-
sumed as an anti-inflammatory cytokine.
The aim of the study was to assess the GDF-15 and 
iron status in patients with early stages of chronic kidney 
disease with particularly emphasis on elderly population. 
Additionally, the association of classic iron status param-
eters with novel iron homeostasis biomarkers and inflam-
matory parameters was investigated.
Patients and methods
Patients with established diagnosis of CKD (n = 87) were 
enrolled to the study. The inclusion criteria were: >18 years 
of age, an estimated glomerular filtration rate (eGFR) ≤60/
ml/min/1.75 m2 or presence of hematuria or proteinuria for 
≥3 months. Exclusion criteria included: clinically active 
acute inflammation (screening C-reactive protein, CRP 
>10 mg/dl) or thrombosis; active oncological disease; acute 
cardiovascular complication (including uncontrolled hyper-
tension, acute coronary syndrome, acute heart failure); any 
anemia and/or iron deficiency treatment; blood transfusions 
within 3 months preceding the study; immunosuppressive 
therapy. The study protocol was approved by the Medi-
cal University Ethics Committee. All patients were fully 
informed about the study and gave their consent.
Medical history (including demographic characteristics 
as well as current pharmacotherapy) and blood samples 
were collected from all the subjects at the time of enrollment 
in the morning after an overnight rest. Diagnosis of CKD in 
>65 years was based the holistic diagnostic approach includ-
ing nephrological and comprehensive geriatric evaluation of 
the patients, including mental status, not exclusively on the 
eGFR critical value of >60 ml/min for more than 3 months. 
We also ruled pout the mental impairment as GDF-15 have 
been associated with cognitive impairment, more common 
in the elderly [7]. Hematological measurements were made 
using fresh venous blood with EDTA and clotted blood. The 
plasma and serum were centrifuging and frozen at −70 °C 
until further laboratory analysis. Patients were divided into 
two groups: ≥65 (n = 56) and <65 (n = 31). Healthy volun-
teers (n = 20) were included in the study to obtain normal 
ranges for studied parameters.
Serum hemoglobin, creatinine, iron, total iron-binding 
capacity (TIBC), and ferritin levels were obtained using 
standard laboratory methods (automated system) in certi-
fied local central laboratory. Transferrin saturation (TSAT) 
was calculated as the ratio of serum iron and TIBC and 
expressed as a percentage. eGFR was calculated from 
chronic kidney disease epidemiology collaboration (CKD-
EPI) equation according to the latest KDIGO guidelines [8].
Commercially available kits were used to measure: 
growth differentiation factor 15—GDF-15 (Quantikine 
ELISA Kit, R&D Systems, Minneapolis, USA), hepci-
din-25 (EIA Kit, Peninsula Laboratories, LLC, Bachem 
Group, USA), soluble transferrin receptor—sTfR (Quan-
tikine IVD ELISA Kit, R&D Systems, Minneapolis, USA), 
interleukin 6—IL-6 (Quantikine ELISA Kit, R&D Sys-
tems, Minneapolis, USA), and high sensitivity C-reactive 
protein—hsCRP (CRP Elisa Kit- LDN Labor Diagnostika 
Nord GmbH&Co KG, Nordhorn, Germany).
Data with normal distribution were reported as 
mean ± standard deviation and non-normally distributed 
as median and interquartile range. Variables with skewed 
distribution were log (ln)-transformed before further statis-
tical analysis. Analyses of the correlation of each param-
eter were performed using Pearson or Spearman correla-
tion coefficients. The multiple regression analysis was used 
to determine independent factors affecting the dependent 
variables. Factors showing linear correlation with GDF-
15 (P < 0.05) were included in the analysis. All statistical 
analyses were performed using Statistica 10.0 (StatSoft, 
Tulsa, OK, USA) computer software.
Results
Table 1 presents clinical and laboratory characteristics 
of the studied population. In patients ≥65 years, serum 
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concentrations of GDF-15 and hsCRP were significantly 
higher, whereas estimated glomerular filtration was lower. 
There was no statistically significant difference in hemo-
globin, iron, hepcidin, and sTfR concentration between 
the two studied groups. In univariate analysis serum iron 
was correlated with IL-6 (r = −0.34, P < 0.05), hsCRP 
(r = −0.53; P < 0.05), and GDF-15 (r = −0.38; P < 0.05) 
only in patients ≥65 years. Positive relation between age 
and GDF-15 (r = 0.35; P < 0.05) was also observed only 
in elderly population. In both groups GDF-15 was signifi-
cantly correlated with hemoglobin (r = −0.52 in patients 
≥65 years; r = −0.46 in patients <65 years; P < 0.05) 
(Fig. 1), eGFR (r = −0.5 in patients ≥65 years; r = −0.53 
in patients <65 years; P < 0.05), and inflammatory param-
eters (Table 2). Hepcidin was significantly correlated with 
ferritin in both groups (Table 3). GDF-15 was significantly 
higher in patients with anemia according to WHO defini-
tion (Hb less than 12 g/dl in women and 13 g/dl in men) 
in comparison with their non-anemic counterparts (Fig. 2). 
In multivariate analysis, hemoglobin was found to be a 
predictor of logGDF-15 (beta value = 0.36, P = 0.006, 
R2 = 37 %). We also found significantly higher concentra-
tions of GDF-15 in patients with type 2 diabetes (n = 22) 
in comparison with non-diabetic patients (median 2694 vs. 
1020, respectively, P < 0.001) (Fig. 3).
Discussion
The present report describes iron status in patients with 
early stages of chronic kidney disease taking into account 
age differences and inflammation. We found that GDF-15 
levels were significantly higher in elderly patients with 
CKD as well as in patients with anemia. In addition, only 
in population over 65 years, GDF-15 was negatively corre-
lated with iron levels. In all the patients, strong correlations 
between inflammatory parameters and iron as well as GDF-
15 were observed. In addition GDF-15 was related to kid-
ney function and hemoglobin. In multiple regression analy-
sis, GDF-15 was predicted independently by hemoglobin. 
However, GDF-15 was not correlated with hepcidin.
GDF-15, also known as macrophage inhibitory 
cytokine-1 (MIC-1), is implicated in immune and inflam-
matory response [9]. We found positive correlations 
between GDF-15 and both IL-6 and hsCRP in our stud-
ied population regardless the age. In patients with end-
stage renal disease, GDF-15 correlation with hsCRP has 
Table 1  Characteristic of the 
study population
* P < 0.05, ** P < 0.01, *** P < 0.001, CKD patients <65 versus >65 years old
# P < 0.05, ### P < 0.001 healthy volunteers versus CKD patients <65 years
<65 years (n = 31) ≥65 years (n = 56) Healthy volunteers (n = 20)
Age, years 57.5 ± 4.2 77.5 ± 6.8*** 51.6 ± 8.8
eGFR, ml/min/1.73 m2 70.8 ± 17.4 60.1 ± 19.2** 98.2 ± 15.6###
GDF-15 (pg/ml) 679.2 (546.9–956.9) 1451.8 (1055.5–2499.4)** 695.0 (515.8–927.5)
Fe (μg/dl) 79.9 ± 32.9 71.2 ± 38 95.9 ± 25.7
TSAT (%) 27.6 ± 10.8 27.6 ± 14.6 29.0 ± 7.1
Ferritin 160.8 (72.4–227.6) 140.9 (91.6–251.8) 108.9 (61.2–159.1)#
Hb (g/dl) 13.2 ± 2 13 ± 2.2 14.0 ± 1.0
hsCRP (mg/l) 3.8 (1.4–16.2) 8.1 (3.8–24.5)* 0.1 (0.1–0.31)###
IL-6 (pg/ml) 0.8 (0.2–5) 2.8 (0.5–6.8) 0.1 (0.01–0.35)###
sTfR (nmol/l) 17.8 (13.7–25) 18.5 (16.6–23.6) 21.2 (15.5–28.3)
Hepcidin (ng/ml) 33.5 (14.2–61.9) 36.2 (28.2–42.3) 23.3 (19.1–31.8)#

















Fig. 1  Correlation between GDF-15 and hemoglobin in patients 
≥65 years (r = −0.52, P < 0.005)
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also been reported [10]. Interestingly, these associations 
remained statistically significant only in patients with-
out anemia (regardless the age). In the study conducted 
by Theurl et al. [11] concerning patients with anemia of 
chronic disease they also did not find a relation between 
GDF-15 and either CRP or IL levels. However, in our study 
GDF-15 levels are significantly increased in patients with 
anemia that is in line with other research [11, 12]. It may 
indicate ineffective erythropoiesis and increased erythroid 
activity [4].
An increase in GDF-15 has been reported in association 
with faster deterioration in kidney function in patients with 
type 1 diabetes [13], as well as after acute kidney injury 
[14]. In the study comprising hemodialysis patients (HD) 
[15], the authors have shown significantly elevated levels 
of GDF-15 in HD population, yet no statistically significant 
relations between GDF-15 and iron status parameters.
In our previous study, BMP-6 and GDF-15, the new 
players of iron metabolism, were assessed in the population 
of HD patients. There were no significant differences in 
BMP6 and GDF-15 levels between patients with and with-
out functional iron deficiency. In this study GDF-15 was 
related hsCRP and NGAL (neutrophil gelatin associated 
lipocalin) in patients without functional iron deficiency, 
while in patients with functional iron deficiency, GDF-15 
was related to serum iron and transferrin saturation. Tanno 
et al. [6] have reported that in patients with thalassemia, 
serum GDF-15 levels are elevated, which results in the sup-
pression of the iron-regulatory protein hepcidin. Significant 
induction of GDF-15 has also been observed in individu-
als with iron deficiency [11, 16]. In our patients with early 
stages of CKD, GDF-15 correlated with kidney function on 
only serum iron levels. In our study we did not find these 
associations that remain in line with HD patients [15].
According to earlier research very high levels of GDF-
15 suppressed the expression of hepcidin [6], whereas 
moderately elevated GDF-15 concentration were positively 
correlated with hepcidin in kidney allograft recipients 
[17] and in elderly individuals with anemia of unknown 
origin [11]. In this study GDF-15 was related to kidney 
function (creatinine r = 0.39, P < 0.01, eGFR by MDRD 
r = −0.37, P < 0.01), urea (r = 0.39, P < 0.01), uric acid 
(r = 0.42, P < 0.01), hepcidin (r = −0.32, P < 0.01), IL-6 
(r = 0.28, P < 0.05), hemoglobin (r = −0.32, P < 0.05), 
and NGAL (r = −0.35, P < 0.01). GDF-15 was not related 
to serum iron, or ferritin. In multivariate analysis, hepcidin 
was found to be a predictor of GDF-15. Similar to our pre-
sent study GDF-15 was significantly higher in patients with 
anemia. In other [18] study on 134 stable heart transplant 
recipients and 157 patients with chronic heart failure, GDF-
15 was significantly higher in patients with anemia com-
pared with non-anemic counterparts in both groups. In uni-
variate analysis in heart transplant recipients, GDF-15 was 
related to kidney function, age, time after transplantation, 
hepcidin, sTfR, hemoglobin, transferrin saturation, ejection 
fraction (EF), and New York Heart Association functional 
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Fig. 2  GDF-15 in patients with and without anemia























Fig. 3  GDF-15 in patients without and with diabetes mellitus
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class. GDF-15 was not related to serum iron or ferritin in 
both groups. In multivariate analysis, sTfR, creatinine, and 
age were found to be predictors of GDF-15. In univariate 
analysis in patients with chronic heart failure, GDF-15 was 
related to creatinine, erythrocyte count, hemoglobin, hep-
cidin, and total iron-binding capacity and tended to corre-
late with EF. In multivariate analysis, hepcidin, creatinine, 
and EF were found to be predictors of GDF-15 in chronic 
heart failure. In population of CHF, there was no correla-
tion between age and GDF-15 (mean age of CHF patients 
was 65.31 ± 10.99 years). In addition, GDF-15 was not 
related to age in kidney allograft recipients (mean age 
44.32 ± 12.23 years) [17]. To assess the effect of age on 
GDF-15, we looked at the possible correlations between 
age and GDF-15 in healthy volunteers. We found that in 
healthy subjects GDF-15 was not related to age. Thus in 
our study higher GDF-15 in the elderly population appears 
not to be related to age but to lower eGFR and lower hemo-
globin. It was hemoglobin, which predicts GDF-15 in 37 % 
in multivariate analysis.
In another population with subclinical inflammatory sta-
tus, both hepcidin and GDF-15 levels were increased and 
showed a positive correlation in anemic patients with type 
2 diabetes [19]. In addition, anemic patients with type 2 
diabetes without overt renal impairment presented a greater 
inflammatory state, with increased serum hsCRP, ESR, 
and IL-6 levels compared with non-anemic counterparts. 
Lindahl [20] in the elegant review stress the role of GDF-
15 as new piece in the puzzle in the world of biomarkers 
as it has been associated with increased cardiovascular as 
well as non-cardiovascular mortality, and development and 
progression of a broad range of diseases, such as coronary 
artery disease, heart failure, diabetes, cancer, and even 
cognitive impairment. Similarly Adela and Banerjee [21] 
in their review paper recognized the relation of high lev-
els of GDF-15 with diabetes, anemia of various etiology, 
and other comorbidities. Moreover, our work is in line with 
the previous findings—patients with type 2 diabetes pre-
sent elevated GDF-15 concentration. It has been shown that 
GDF-15 may be a predictor of several outcomes in type 2 
diabetes [22].
To summarize, as data regarding pathophysiological role 
of GDF-15 in diabetes, kidney disease and other comor-
bidities are limited, associations between renal function, 
anemia and GDF-15 concentrations awaits further studies. 
Explaining the signaling pathways of GDF-15 may help to 
understand the exciting puzzle of GDF-15. Normal levels 
of GDF-15 in the healthy aged were not studied, and the 
higher values of GDF-15 values found in the present study 
may possibly be due to age more than CKD levels.
Acknowledgments The research received no specific grant from 
any founding agency.
Compliance with ethical standards 
Conflict of interests All the authors declare no conflict of interests.
Open Access This article is distributed under the terms of the 
Creative Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.  
References
 1. Lindeman RD, Tobin J, Shock NW (1984) Association between 
blood pressure and the rate of decline in renal function with age. 
Kidney Int 26:861–868
 2. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS (2003) 
Prevalence of chronic kidney disease and decreased kidney func-
tion in the adult US population: third national health and nutri-
tion examination survey. Am J Kidney Dis 41:1–12
 3. Malyszko J, Bachorzewska-Gajewska H, Malyszko JS, Dobr-
zycki S (2010) Prevalence of chronic kidney disease in elderly 
patients with normal serum creatinine levels undergoing percuta-
neous coronary interventions. Gerontology 56:51–54
 4. Tanno T, Noel P, Miller JL (2010) Growth differentiation fac-
tor 15 in erythroid health and disease. Curr Opin Hematol 
17:184–190
 5. Tanno T, Bhanu NV, Oneal PA, Goh SH, Staker P, Lee YT, 
Moroney JW, Reed CH, Luban NL, Wang RH, Eling TE, Childs 
R, Ganz T, Leitman SF, Fucharoen S, Miller JL (2007) High 
levels of GDF15 in thalassemia suppress expression of the iron 
regulatory protein hepcidin. Nat Med 13:1096–1101
 6. Ho JE, Hwang SJ, Wollert KC, Larson MG, Cheng S, Kempf T, 
Vasan RS, Januzzi JL, Wang TJ, Fox CS (2013) Biomarkers of 
cardiovascular stress and incident chronic kidney disease. Clin 
Chem 59:1613–1620
 7. Fuchs T, Trollor JN, Crawford J, Brown DA, Baune BT, Samaras 
K, Campbell L, Breit SN, Brodaty H, Sachdev P, Smith E (2013) 
Macrophage inhibitory cytokine-1 is associated with cognitive 
impairment and predicts cognitive decline—the Sydney Memory 
and Aging Study. Aging Cell 12:882–889
 8. KDIGO (2012) Clinical practice guideline for the evaluation 
and management of chronic kidney disease. Kidney Int Suppl 
2013(3):1–150
 9. Bootcov MR, Bauskin AR, Valenzuela SM, Moore AG, Bansal 
M, He XY, Zhang HP, Donnellan M, Mahler S, Pryor K, Walsh 
BJ, Nicholson RC, Fairlie WD, Por SB, Robbins JM, Breit SN 
(1997) MIC-1, a novel macrophage inhibitory cytokine, is a 
divergent member of the TGF-beta superfamily. Proc Natl Acad 
Sci USA 94:11514–11519
 10. Breit SN, Carrero JJ, Tsai VW, Yagoutifam N, Luo W, Kuffner 
T, Bauskin AR, Wu L, Jiang L, Barany P, Heimburger O, 
Murikami MA, Apple FS, Marquis CP, Macia L, Lin S, Sains-
bury A, Herzog H, Law M, Stenvinkel P, Brown DA (2012) 
Macrophage inhibitory cytokine-1 (MIC-1/GDF15) and mor-
tality in end-stage renal disease. Nephrol Dial Transplant 
27:70–75
 11. Theurl I, Finkenstedt A, Schroll A, Nairz M, Sonnweber T, Bell-
mann-Weiler R, Theurl M, Seifert M, Wroblewski VJ, Murphy 
AT, Witcher D, Zoller H, Weiss G (2010) Growth differentiation 
factor 15 in anaemia of chronic disease, iron deficiency anaemia 
and mixed type anaemia. Br J Haematol 148:449–455
844 Int Urol Nephrol (2016) 48:839–844
1 3
 12. Waalen J, von Löhneysen K, Lee P, Xu X, Friedman JS (2011) 
Erythropoietin, GDF15, IL6, hepcidin and testosterone levels in 
a large cohort of elderly individuals with anaemia of known and 
unknown cause. Eur J Haematol 87:107–116
 13. Lajer M, Jorsal A, Tarnow L, Parving HH, Rossing P (2010) 
Plasma growth differentiation factor-15 independently predicts 
all-cause and cardiovascular mortality as well as deterioration 
of kidney function in type 1 diabetic patients with nephropathy. 
Diabetes Care 33:1567–1572
 14. Zimmers TA, Jin X, Hsiao EC, McGrath SA, Esquela AF, Koni-
aris LG (2005) Growth differentiation factor-15⁄macrophage 
inhibitory cytokine-1 induction after kidney and lung injury. 
Shock 23:543–548
 15. Li XY, Ying J, Li JH, Zhu SL, Li J, Pai P (2015) Growth dif-
ferentiation factor GDF-15 does not influence iron metabolism 
in stable chronic haemodialysis patients. Ann Clin Biochem 
52:399–403
 16. Lakhal S, Talbot NP, Crosby A, Stoepker C, Townsend AR, Rob-
bins PA, Pugh CW, Ratcliffe PJ, Mole DR (2009) Regulation of 
growth differentiation factor 15 expression by intracellular iron. 
Blood 113:1555–1563
 17. Malyszko J, Koc-Zorawska E, Malyszko JS, Glowinska I, Mys-
liwiec M, Macdougall IC (2013) GDF15 is related to anemia 
and hepcidin in kidney allograft recipients. Nephron Clin Pract 
123:112–117
 18. Przybyłowski P, Wasilewski G, Bachorzewska-Gajewska H, 
Golabek K, Dobrzycki S, Małyszko J (2014) Growth differentia-
tion factor 15 is related to anemia and iron metabolism in heart 
allograft recipients and patients with chronic heart failure. Trans-
plant Proc 46:2852–2855
 19. Hong JH, Choi YK, Min BK, Park KS, Seong K, Lee IK, Kim 
JG (2015) Relationship between hepcidin and GDF15 in anemic 
patients with type 2 diabetes without overt renal impairment. 
Diabetes Res Clin Pract 109:64–70
 20. Lindahl B (2013) The story of growth differentiation factor 15: 
another piece of the puzzle. Clin Chem 59:1550–1552
 21. Adela R, Banerjee SK (2015) GDF-15 as a target and biomarker 
for diabetes and cardiovascular diseases: a translational prospec-
tive. J Diabetes Res 2015:490842
 22. Berezin AE (2015) Diabetes mellitus related biomarker: the 
predictive role of growth-differentiation factor-15, diabetes and 
metabolic syndrome: clinical research and reviews. http://dx.doi.
org/10.1016/j.dsx.2015.09.01
